Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis

Background: Patients with indolent systemic mastocytosis (ISM), a clonal mast cell disease primarily driven by the KIT D816V mutation, often have lifelong debilitating symptoms. Anaphylaxis is a common feature of the disease seen in up to half of patients. The effects of KIT D816V-targeted therapy o...

Полное описание

Библиографические подробности

Главные авторы:	Thanai Pongdee, MD, Mariana Castells, MD, PhD, Cem Akin, MD, Ingunn Dybedal, MD, PhD, Jason Gotlib, MD, Jens Peter Panse, MD, Ivan Alvarez-Twose, MD, PhD, Cristina Morales Cabeza, MD, Sonia Cerquozzi, MD, FRCPC, Peter Vadas, MD, Vidushi Swarup, MS, Pankit Vachhani, MD, Friederike Wortmann, MD, Cecilia Arana Yi, MD, Ilda Bidollari, MD, Kate Newberry, PhD, Daniel Shaheen, PharmD, Karin Hartmann, MD
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2026-04-01
Серии:	World Allergy Organization Journal
Предметы:	Anaphylaxis Indolent systemic mastocytosis Avapritinib
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S1939455126001857
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!